Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction

Journal of Thrombosis and Thrombolysis

Volumn 26, Issue 3, 2008, Pages 234-242

  Kunadian, Vijayalakshmi ^a   Zorkun, Cafer ^a   Williams, Scott P ^a   Biller, Leah H ^a   Palmer, Alexandra M ^a   Ogando, Katherine J ^a   Lew, Michelle E ^a   Nethala, Navin ^a   Gibson, William J ^a   Marble, Susan J ^a   Buros, Jacqueline L ^a   Gibson, C Michael ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Microcirculation; Myocardial infarction; Perfusion; Vasoconstriction

Indexed keywords

ABCIXIMAB; ADENOSINE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA 2 ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; EPTIFIBATIDE; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; GLYCOPROTEIN IIB INHIBITOR; NICARDIPINE; NICORANDIL; NITROPRUSSIDE SODIUM; PAPAVERINE; PHENTOLAMINE; PLACEBO; PROTEIN INHIBITOR; STREPTOKINASE; TENECTEPLASE; TIROFIBAN; UNCLASSIFIED DRUG; URAPIDIL; VASODILATOR AGENT; VERAPAMIL; YOHIMBINE;

ADJUVANT THERAPY; BLEEDING; BOLUS INJECTION; BRADYCARDIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CORONARY ARTERY BLOOD FLOW; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEART ARRHYTHMIA; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; INTRACORONARY INFUSION; LOW DRUG DOSE; MICROANGIOPATHY; MONOTHERAPY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; TACHYCARDIA; THORAX PAIN; THROMBOSIS;

ACUTE CORONARY SYNDROME; CLINICAL TRIALS AS TOPIC; CORONARY CIRCULATION; HUMANS; INFUSIONS, INTRA-ARTERIAL; MICROVESSELS; MYOCARDIAL REPERFUSION; NO-REFLOW PHENOMENON;

EID: 56349090392     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0276-0     Document Type: Review

References (73)

1. Roe MT, Ohman EM, Maas AC, Christenson RH, Mahaffey KW, Granger CB et al (2001) Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion. J Am Coll Cardiol 37:9-18. doi: 10.1016/ S0735-1097(00)01101-3
2. Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K (2005) Epicardial and microvascular reperfusion with primary percutaneous coronary intervention. Ital Heart J 6:447-452
3. Ambrosio G, Tritto I (1999) Reperfusion injury: Experimental evidence and clinical implications. Am Heart J 138:S69-S75. doi: 10.1016/ S0002-8703(99)70323-6
4. Michaels AD, Gibson CM, Barron HV (2000) Microvascular dysfunction in acute myocardial infarction: Focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol 85:50B-60B. doi: 10.1016/S0002-9149(00)00811-0
5. Forman MB, Jackson EK (2007) Importance of tissue perfusion in ST segment elevation myocardial infarction patients undergoing reperfusion strategies: Role of adenosine. Clin Cardiol 30:583-585. doi: 10.1002/ clc.20183
6. Forman MB, Stone GW, Jackson EK (2006) Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 24:116-147. doi: 10.1111/j.1527-3466.2006.00116.x
7. Olafsson B, Forman M, Puett D, Cates C, Friesinger G, Virmani R (1987) Reduction of reperfusion injury in the canine preparation by intracoronary adenosine. Circulation 76:1135-1145
8. Minamino T, Kitakaze M, Asanuma H, Tomiyama Y, Shiraga M, Sato H et al (1998) Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs. J Clin Invest 101:1643-1653. doi: 10.1172/JCI635
9. Wilson R, Wyche K, Christensen B, Zimmer S, Laxson D (1990) Effects of adenosine on human coronary arterial circulation. Circulation 82:1595-1606
10. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF et al (1999) Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34:1711-1720. doi: 10.1016/ S0735-1097(99)00418-0
11. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW (2005) A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45:1775-1780. doi: 10.1016/j.jacc.2005.02.061
12. Marzilli M, Orsini E, Marracini P, Testa T (2000) Beneficial effects of intracoronary adenosine as adjunct to primary angioplasty in acute myocardial infarction. Circulation 101:2154-2159
13. Lee CH, Low A, Tai BC, Co M, Chan MY, Lim J et al (2007) Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: A prospective randomized study. Eur Heart J 28:19-25. doi: 10.1093/eurheartj/ehl411
14. Desmet WJ, Dens J, Coussement P, Van de WF (2002) Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. ADEnosine Limit myocardial Necrosis. Heart 88:293-295. doi: 10.1136/heart.88.3.293
15. Assali AR, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna GP et al (2000) Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc Interv 51:27-31. doi:10.1002/ 1522-726X(200009)51:1<27::AID-CCD7>3.0.CO;2-0
16. Hanna GP, Yhip P, Fujise K, Schroth GW, Rosales OR, Anderson HV et al (1999) Intracoronary adenosine administered during rotational atherectomy of complex lesions in native coronary arteries reduces the incidence of no-reflow phenomenon. Catheter Cardiovasc Interv 48:275-278. doi:10.1002/ (SICI)1522-726X(199911)48:3<275::AID-CCD8>3.0.CO;2-M
17. Gibson CM (2003) Has my patient achieved adequate myocardial reperfusion? Circulation 108:504-507. doi: 10.1161/ 01.CIR.0000082932.69023.74
18. Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von BC, Zijlstra F (2008) High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo-controlled pilot study. Catheter Cardiovasc Interv 71:283-289. doi: 10.1002/ccd.21334
19. Fischell TA, Carter AJ, Foster MT, Hempsall K, DeVries J, Kim DH et al (1998) Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 45:360-365. doi:10.1002/ (SICI)1097-0304(199812)45:4<360::AID-CCD1>3.0.CO;2-R
20. Sdringola S, Assali A, Ghani M, Yepes A, Rosales O, Schroth GW et al (2000) Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv 51:394-399. doi:10.1002/ 1522-726X(200012)51:4<394::AID-CCD4>3.0.CO;2-G
21. Taniyama Y, Ito H, Iwakura K (1997) Beneficial effects of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 30:1193-1199. doi: 10.1016/ S0735-1097(97)00277-5
22. Umemura S, Nakamura S, Sugiura T, Tsuka Y, Fujitaka K, Yoshida S et al (2006) The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographic no-reflow after primary percutaneous coronary intervention. Nucl Med Commun 27:247-254. doi: 10.1097/00006231-200603000-00007
23. Vijayalakshmi K, Whittaker VJ, Kunadian B, Graham J, Wright RA, Hall JA et al (2006) Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 92:1278-1284. doi: 10.1136/ hrt.2005.075077
24. Piani R, Palik G, Moscucci M, Cohen D, Gibson M, Kugelmass A et al (1994) Incidence and treatment of 'No-Reflow' after percutaneous coronary intervention. Circulation 89:2514-2518
25. Oldenburg O, Eggerbrecht H, Herrmann J, Naber C (2000) Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. Cardiovasc Drugs Ther 14:651-655. doi: 10.1023/ A:1007823116491
26. Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM et al (2002) Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: Results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 14:299-302
27. Rossen JD, Simonetti I, Marcus ML, Braun P, Winniford MD (1989) The effect of diltiazem on coronary flow reserve in humans. Circulation 80:1240-1246
28. McIvor ME, Undemir C, Lawson J, Reddinger J (1995) Clinical effects and utility of intracoronary diltiazem. Cathet Cardiovasc Diagn 35:287-291. doi: 10.1002/ccd.1810350402, discussion
29. Fugit MD, Rubal BJ, Donovan DJ (2000) Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol 12:80-85
30. Huang RI, Patel P, Walinsky P, Fischman DL, Ogilby JD, Awar M et al (2006) Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv 68:671-676. doi: 10.1002/ccd.20885
31. Myers PR, Banitt PF, Guerra R Jr, Harrison DG (1989) Characteristics of canine coronary resistance arteries: Importance of endothelium. Am J Physiol 257:H603-H610
32. Kuo L, Chilian WM, Davis MJ (1991) Interaction of pressure- and flow-induced responses in porcine coronary resistance vessels. Am J Physiol 261:H1706-H1715
33. Bates JN, Baker MT, Guerra R Jr, Harrison DG (1991) Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol 42(suppl):S157-S165. doi: 10.1016/0006-2952(91)90406-U
34. Harrison DG, Bates JN (1993) The nitrovasodilators. New ideas about old drugs. Circulation 87:1461-1467
35. Kurz MA, Lamping KG, Bates JN, Eastham CL, Marcus ML, Harrison DG (1991) Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res 68:847-855
36. Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A et al (2005) Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 95:1358-1361. doi: 10.1016/j.amjcard.2005.01.082
37. Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS (2004) Treatment of slow/ no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 63:171-176. doi: 10.1002/ccd.20149
38. Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Bu-Ful A, Weinstein JM, Wolak A, Ilia R, Zahger D (2006) Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 152:814-887. doi: 10.1016/j.ahj.2006.05.010
39. Parham WA, Bouhasin A, Ciaramita JP, Khoukaz S, Herrmann SC, Kern MJ (2004) Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation 109:1236-1243. doi: 10.1161/ 01.CIR.0000118470.52908.D9
40. Barcin C, Denktas AE, Lennon RJ, Hammes L, Higano ST, Holmes DR Jr et al (2004) Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv 61:484-491. doi: 10.1002/ccd.20010
41. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR (2001) Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: Initial human clinical experience. J Am Coll Cardiol 37:1335-1343. doi: 10.1016/ S0735-1097(01)01138-X
42. Taira N (1989) Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 63:18J-24J. doi: 10.1016/ 0002-9149(89)90200-2
43. Taira N (1987) Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: An overview. J Cardiovasc Pharmacol 10(suppl 8):S1-S9
44. Lim SY, Bae EH, Jeong MH, Kang DG, Lee YS, Kim KH et al (2004) Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J 68:928-932. doi: 10.1253/circj.68.928
45. Ota S, Nishikawa H, Takeuchi M, Nakajima K, Nakamura T, Okamoto S et al (2006) Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J 70:1099-1104. doi: 10.1253/ circj.70.1099
46. Wilson RF, White CW (1986) Intracoronary papaverine: An ideal coronary vasodilator for studies of the coronary circulation in conscious humans. Circulation 73:444-451
47. Zijlstra F, Serruys PW, Hugenholtz PG (1986) Papaverine: The ideal coronary vasodilator for investigating coronary flow reserve? A study of timing, magnitude, reproducibility, and safety of the coronary hyperemic response after intracoronary papaverine. Cathet Cardiovasc Diagn 12:298-303. doi: 10.1002/ccd.1810120505
48. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S et al (1996) Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 132:959-963. doi: 10.1016/S0002-8703(96)90005-8
49. Inoue T, Asahi S, Takayanagi K, Morooka S, Takabatake Y (1994) QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine. Cardiology 84:9-13
50. Wilson RF, White CW (1988) Serious ventricular dysrhythmias after intracoronary papaverine. Am J Cardiol 62:1301-1302. doi: 10.1016/ 0002-9149(88)90281-0
51. Skelding KA, Goldstein JA, Mehta L, Pica MC, O'Neill WW (2002) Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv 57:305-309. doi: 10.1002/ccd.10303
52. Heusch G (1990) Alpha-adrenergic mechanisms in myocardial ischemia. Circulation 81:1-13
53. Jones CJ, DeFily DV, Patterson JL, Chilian WM (1993) Endothelium-dependent relaxation competes with alpha 1- and alpha 2-adrenergic constriction in the canine epicardial coronary microcirculation. Circulation 87:1264-1274
54. Gregorini LM, Marco JM, Kozakova MM, Palombo CM, Anguissola GBM, Marco IM et al (1999) Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 99:482-490, Article
55. Gregorini L, Marco J, Farah B, Bernies M, Palombo C, Kozakova M et al (2002) Effects of selective alpha1- and alpha2-adrenergic blockade on coronary flow reserve after coronary stenting. Circulation 106:2901-2907. doi: 10.1161/01.CIR.0000040998.88272.A7
56. Wohrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M et al (2003) Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 107:1840-1843. doi: 10.1161/ 01.CIR.0000066852.98038.D1
57. Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F (2007) Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 23:57-63. doi: 10.1007/s11239-006-9000-0
58. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE (1996) Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 88:907-914
59. Gibson CM, Jennings LK, Murphy SA, Lorenz DP, Giugliano RP, Harrington RA et al (2004) Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: An INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation 110:679-684. doi: 10.1161/01.CIR.0000137912.11655.F6
60. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK (1997) 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 17:528-535
61. Kintscher U, Kappert K, Schmidt G, Doerr G, Grill M, Wollert-Wulf B et al (2000) Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells. Eur J Pharmacol 390:75-87. doi: 10.1016/S0014-2999(99)00912-7
62. Thiele H, Schindler K, Friedenberger J, Eitel I, Furnau G, Grebe E et al (2008) Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118:49-57. doi: 10.1161/CIRCULATIONAHA.107.747642
63. Pinto DS, Kirtane AJ, Ruocco NA, Deibele AJ, Shui A, Buros J et al (2005) Administration of intracoronary eptifibatide during ST-elevation myocardial infarction. Am J Cardiol 96:1494-1497. doi: 10.1016/ j.amjcard.2005.07.056
64. Timurkaynak T, Cemri M, Ozdemir M, Yalcin R, Cengel A, Dortlemez O (2001) Adjunctive therapies in the cath lab. Intracoronary tirofiban infusion in a case with massive intracoronary thrombus. J Invasive Cardiol 13:654-656
65. Yang TY, Chang ST, Chung CM, Cheng NJ (2005) Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment. Int Heart J 46:139-145. doi: 10.1536/ihj.46.139
66. Yang XC, Zhang DP, Wang LF, Xu L, Ge YG, Wang HS et al (2007) Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi 35:517-522
67. Ozeren A, Aydin M, Ozkokeli M, Unalacak M, Bilge M (2004) Treatment of intracoronary thrombus using tirofiban in a patient with normal coronary arteries. Jpn Heart J 45:343-346. doi: 10.1536/jhj.45.343
68. Ben-Ami R, Sheinman G, Yedgar S, Eldor A, Roth A, Berliner AS et al (2002) Thrombolytic therapy reduces red blood cell aggregation in plasma without affecting intrinsic aggregability. Thromb Res 105:487-492. doi: 10.1016/S0049-3848(02)00052-X
69. Woo KS, Armiger LC, White HD, Norris RM (2000) Can streptokinase produce beneficial effects additional to coronary recanalization? Quantitative microvascular analysis of critically injured reperfused myocardium. Microvasc Res 60:8-20. doi: 10.1006/mvre.2000.2236
70. Sezer M, Oflaz H, Goren T, Okcular I, Umman B, Nisanci Y et al (2007) Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 356:1823-1834. doi: 10.1056/NEJMoa054374
71. Kelly RV, Crouch E, Krumnacher H, Cohen MG, Stouffer GA (2005) Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: Initial experience with intracoronary tenecteplase. Catheter Cardiovasc Interv 66:327-332. doi: 10.1002/ccd.20521
72. Abbas AE, Brewington SD, Dixon SR, Boura JA, Grines CL, O'Neill WW (2005) Intracoronary fibrin-specific thrombolytic infusion facilitates percutaneous recanalization of chronic total occlusion. J Am Coll Cardiol 46:793-798. doi: 10.1016/j.jacc.2005.05.055
73. Leesar MA, Jneid H, Tang XL, Bolli R (2007) Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty. J Am Coll Cardiol 49:1607-1610. doi: 10.1016/ j.jacc.2007.01.060